RESUMO
OBJECTIVE: In complicated parapneumonic effusion or Empyema, approximately 25% of patients require surgical intervention which can be associated with a mortality risk of almost 20%. However, the use combination of rt-tPA and DNase in elderly patients with prohibitive surgical risk has improved outcomes. The main goal of our study is to highlight the utility of intrapleural thrombolysis in patients with prohibitive risk for surgery. METHODS: A retrospective record review study of patients (n=23) with complicated parapneumonic pleural effusion or empyema treated with tPA and DNase from January 1st of 2015 to March 18th, 2019 at VACHCS. Data collected to describe the outcome of intrapleural thrombolytics included demographic, pleural fluid analysis, surgical risk assessment, diagnosis and initiation treatment day, doses, chest imaging, drainage rate, chest tube size and average days in place, inflammatory markers, microbiology, antibiotics, and complications. RESULTS: Only 21.7% of patients were considered surgical candidates. Seventy-four percent had a 30-day post-surgical mortality risk of > 2.5% using the National Surgery Office (NSO) risk calculator. Post-operative inpatient stay was 99.7% and estimated post operative ICU stay average was >80%. Primary outcome (pleural drainage improvement) obtained in 73.9%. Most common serious complications included sepsis (52.2%) and nonserious was residual hydropneumothorax (47.8%). CONCLUSION: This study demonstrates that administration of intrapleural thrombolytics through a percutaneous pleural catheter achieved successful drainage safely and without the need for surgical interventions in a selected group of advanced age, elderly patients with pleural infections who were deemed to be high surgical risk.
Assuntos
Empiema , Derrame Pleural , Idoso , Humanos , Estudos Retrospectivos , Derrame Pleural/etiologia , Derrame Pleural/terapia , Fibrinolíticos , DesoxirribonucleasesRESUMO
Abstract The authors report the case of a 71-year-old woman presented to the Emergency Department with acute ischemic stroke. She was treated with rt-PA and interventional endovascular revascularization and developed rapidly progressing angioedema that led to emergency intubation. The standard treatment was not very effective and the swelling improved after infusion of fresh frozen plasma. Angioedema after rt-PA infusion could be a life-threatening emergency that requires quick airway management by skilled professionals. As this condition is triggered by several factors, such as unregulated histamine and bradykinin production, the traditional treatment recommended by the guidelines may not be sufficient and the use of FFP can be considered as a safe and valuable aid.
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Idoso , AVC Isquêmico/complicações , Angioedema/induzido quimicamente , Angioedema/terapia , Plasma , Histamina , Manuseio das Vias AéreasRESUMO
The authors report the case of a 71-year-old woman presented to the Emergency Department with acute ischemic stroke. She was treated with rt-PA and interventional endovascular revascularization and developed rapidly progressing angioedema that led to emergency intubation. The standard treatment was not very effective and the swelling improved after infusion of fresh frozen plasma. Angioedema after rt-PA infusion could be a life-threatening emergency that requires quick airway management by skilled professionals. As this condition is triggered by several factors, such as unregulated histamine and bradykinin production, the traditional treatment recommended by the guidelines may not be sufficient and the use of FFP can be considered as a safe and valuable aid.
Assuntos
Angioedema , AVC Isquêmico , Feminino , Humanos , Idoso , AVC Isquêmico/complicações , Angioedema/induzido quimicamente , Angioedema/terapia , Manuseio das Vias Aéreas , Histamina , PlasmaRESUMO
Resumen El factor de riesgo más importante para presentar una enfermedad cerebrovascular (EVC) es la edad. El ictus es la causa más frecuente de discapacidad adquirida en la edad adulta. De acuerdo con la Organización Mundial de la Salud, se estima que en el año 2050, casi la mitad de la población mayor de 65 años podría sufrir o haber sufrido un EVC. Debido a la gran incidencia y al impacto negativo que tiene esta enfermedad, presentamos el caso clínico de una trombólisis exitosa en una paciente con ictus isquémico y crisis hipertensiva en el Servicio de Urgencias. Ponemos de manifiesto la adecuada evaluación con las diferentes escalas existentes, clínicas, radiológicas y pronósticas (NIHSS, Dragon Score, ASPECT, HAT score), así como los criterios de inclusión y exclusión, los cuales son indispensables para administrar una terapia de repercusión intravenosa. Conclusiones En México, los casos reportados con trombólisis exitosa son sólo el 5%. En este caso de éxito, la adecuada actuación en el Servicio de Urgencias de primer contacto impactó de manera positiva en el pronóstico de la paciente, ya que el diagnóstico oportuno y la administración de rTPA (activador tisular del plasminógeno) evitó secuelas importantes y consiguió una mejor calidad de vida -la cual se ve disminuida hasta en 70% de los pacientes que sufren un EVC (según estudios realizados en los EUA)-.
Abstract The most important risk factor for presenting a cerebrovascular disease (CVA) is age. Stroke is also the most frequent cause of disability acquired in adulthood. According to the World Health Organization, it is estimated that by the year 2050, almost half of the population over 65 could suffer or have suffered a CVA. Due to the high incidence and negative impact of this disease, we present a clinical case of successful thrombolysis in a patient with ischemic stroke and hypertensive crisis in the emergency department. We emphasize the adequate evaluation with the different existing clinical, radiological and predictive scales (NIHSS, Dragon Score, ASPECT, HAT score), as well as the inclusion and exclusion criteria, which are indispensable to administer an intravenous reperfusion therapy. Conclusions In Mexico, the cases reported with successful thrombolysis are only 5%. In this successful case, the proper performance in the emergency service impacted positively on the prognosis of the patient, since the timely diagnosis and administration of rTPA avoided important sequelae and provided a better quality of Life, which is decreased in up to 70% of patients suffering from a CVA (according to studies conducted in the USA).
RESUMO
INTRODUCTION: The incidence of cardiac thrombi in newborns has increased with the use of central venous catheters. Thrombolysis with recombinant tissue plasminogen activator (rTPA) has been used as an alternative to heparin in life threatening giant thrombus and embolization. The aim of this study is to describe the response and complications related to the use of rTPA in the management of life- threatening cardiac thrombi in newborns. PATIENTS AND METHOD: The medical records of 8 newborn were reviewed in a retrospective study, of whom 7 were preterm with cardiac thrombi, and rTPA was used in all of them. RESULTS: The patients included 4 males with a mean weight of 1580 gr. The principal pathology was sepsis (7/8), all of them used venous central catheter. The superior vena cava was the most frequent location, with a mean time of installation before the diagnosis of 12 days. RN 7/8 thrombi were located in the right atrium with a size between 7 to 20 mm. Three patients received low molecular weight heparin prior to using rTPA. They received between 1 to 5 cycles with rTPA. In 4 patients complete resolution of the thrombus was achieved in a mean of 3.5 days. Four patients had intracranial haemorrhage grade I, without sequelae at follow-up. There were no deaths or embolism. CONCLUSION: This study is the first series of infants treated with rTPA in Chile, and where its use has quickly achieved complete resolution of the thrombus in 50% of cases, and partially in the others, thus reducing the secondary life-threatening risk of this disease.
Assuntos
Fibrinolíticos/administração & dosagem , Cardiopatias/tratamento farmacológico , Trombose/tratamento farmacológico , Ativador de Plasminogênio Tecidual/administração & dosagem , Cateteres Venosos Centrais , Chile , Feminino , Fibrinolíticos/efeitos adversos , Fibrinolíticos/uso terapêutico , Seguimentos , Cardiopatias/patologia , Heparina/administração & dosagem , Humanos , Recém-Nascido , Hemorragias Intracranianas/induzido quimicamente , Hemorragias Intracranianas/epidemiologia , Masculino , Estudos Retrospectivos , Terapia Trombolítica/efeitos adversos , Terapia Trombolítica/métodos , Trombose/patologia , Fatores de Tempo , Ativador de Plasminogênio Tecidual/efeitos adversos , Ativador de Plasminogênio Tecidual/uso terapêutico , Resultado do TratamentoRESUMO
Introducción: La incidencia de trombos cardíacos en recién nacidos (RN) ha aumentado con el uso de catéteres venosos centrales. La trombólisis con activador del plasminógeno tisular recombinante (rTPA) se ha utilizado como alternativa a la heparina en trombos gigantes con riesgo vital y de embolización. Nuestro objetivo fue describir la respuesta y las complicaciones relacionadas con el uso del rTPA en el manejo de trombos cardíacos con riesgo vital en RN. Pacientes y método: Estudio retrospectivo de 8 RN, 7 prematuros, con trombos cardíacos en los cuales se utilizó rTPA. Se analizó la edad gestacional y al diagnóstico, peso, sexo, enfermedades asociadas, hemograma, niveles de fibrinógeno, dímero D, tiempo parcial de tromboplastina activada y de protrombina, antes y al término de la infusión de rTPA. El diagnóstico del trombo se realizó por ecocardiografía doppler. La indicación de rTPA fue trombo mayor de 10 mm o que ocupara más del 50% de la cavidad donde se localizaba; aumento del tamaño a pesar del tratamiento con heparina, aspecto fragmentado y lobulado con riesgo embólico pulmonar o sistémico o que comprometiera la función valvular o cardíaca. Resultados: Cuatro hombres; peso promedio de 1.580 g. La principal enfermedad fue la sepsis (7/8), se usó catéter venoso central en todos, la vena cava superior fue la localización más frecuente, con tiempo promedio de instalación previo al diagnóstico de 12 días. En 7/8 RN los trombos se ubicaron en la aurícula derecha, con un tamaño entre 7 a 20 mm. Tres pacientes recibieron heparina de bajo peso molecular previo al uso de rTPA, se realizaron entre uno a 5 ciclos con rTPA. En 4 pacientes se logró resolución completa del trombo a los 3,5 días en promedio. No hubo embolia ni fallecidos. Cuatro pacientes presentaron hemorragia intracraneana grado I, sin secuelas en el seguimiento. Conclusión: Este estudio constituye la primera serie de neonatos tratados con rTPA en Chile, lográndose la resolución completa del trombo en un 50% de los RN y parcial en el resto, permitiendo con ello disminuir el riesgo vital secundario a este proceso patológico.
Introduction: The incidence of cardiac thrombi in newborns has increased with the use of central venous catheters. Thrombolysis with recombinant tissue plasminogen activator (rTPA) has been used as an alternative to heparin in life threatening giant thrombus and embolization. The aim of this study is to describe the response and complications related to the use of rTPA in the management of life- threatening cardiac thrombi in newborns. Patients and method: The medical records of 8 newborn were reviewed in a retrospective study, of whom 7 were preterm with cardiac thrombi, and rTPA was used in all of them. Results: The patients included 4 males with a mean weight of 1580 gr. The principal pathology was sepsis (7/8), all of them used venous central catheter. The superior vena cava was the most frequent location, with a mean time of installation before the diagnosis of 12 days. RN 7/8 thrombi were located in the right atrium with a size between 7 to 20 mm. Three patients received low molecular weight heparin prior to using rTPA. They received between 1 to 5 cycles with rTPA. In 4 patients complete resolution of the thrombus was achieved in a mean of 3.5 days. Four patients had intracranial haemorrhage grade I, without sequelae at follow-up. There were no deaths or embolism. Conclusion: This study is the first series of infants treated with rTPA in Chile, and where its use has quickly achieved complete resolution of the thrombus in 50% of cases, and partially in the others, thus reducing the secondary life-threatening risk of this disease.
Assuntos
Humanos , Masculino , Feminino , Recém-Nascido , Trombose/tratamento farmacológico , Ativador de Plasminogênio Tecidual/administração & dosagem , Fibrinolíticos/administração & dosagem , Cardiopatias/tratamento farmacológico , Fatores de Tempo , Heparina/administração & dosagem , Terapia Trombolítica/efeitos adversos , Chile , Estudos Retrospectivos , Seguimentos , Resultado do Tratamento , Ativador de Plasminogênio Tecidual/efeitos adversos , Ativador de Plasminogênio Tecidual/uso terapêutico , Hemorragias Intracranianas/induzido quimicamente , Hemorragias Intracranianas/epidemiologia , Fibrinolíticos/efeitos adversos , Fibrinolíticos/uso terapêutico , Cateteres Venosos Centrais , Cardiopatias/patologiaRESUMO
Since the inflammatory response and oxidative stress are involved in the stroke cascade, we evaluated here the effects of Phycocyanobilin (PCB, the C-Phycocyanin linked tetrapyrrole) on PC12 cell survival, the gene expression and the oxidative status of hypoperfused rat brain. After the permanent bilateral common carotid arteries occlusion (BCCAo), the animals were treated with saline or PCB, taking samples 24h post-surgery. Global gene expression was analyzed with GeneChip Rat Gene ST 1.1 from Affymetrix; the expression of particular genes was assessed by the Fast SYBR Green RT-PCR Master Mix and Bioplex methods; and redox markers (MDA, PP, CAT, SOD) were evaluated spectrophotometrically. The PCB treatment prevented the H2O2 and glutamate induced PC12 cell injury assessed by the MTT assay, and modulated 190 genes (93 up- and 97 down-regulated) associated to several immunological and inflammatory processes in BCCAo rats. Furthermore, PCB positively modulated 19 genes mostly related to a detrimental pro-inflammatory environment and counteracted the oxidative imbalance in the treated BCCAo animals. Our results support the view of an effective influence of PCB on major inflammatory mediators in acute cerebral hypoperfusion. These results suggest that PCB has a potential to be a treatment for ischemic stroke for which further studies are needed.